Heinz Reichmann, MD, PhD, University of Dresden, Dresden, Germany, discusses potential therapeutic strategies for Parkinson’s disease (PD). Firstly, if an antibody could stop the propagation of abnormal alpha-synuclein, the disease could potentially be stopped. Secondly, LRRK2 (leucine-rich repeat kinase 2) mutations are abundantly found in PD patients in places like Northern Africa and Israel. Therefore, the development of LRRK2 inhibitors could offer the prospect of a novel disease-modifying treatment. Finally, genetic research has shown that there are three genes related to the biogenesis of mitochondria – PINK1, PARKIN, and DJ-1. This research has resulted in the development of medication targeting these mitochondrial problems. Overall, research shows potential other targets aside from dopamine-replacement therapy or anti-inflammatory drugs. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.